CompletedNot Applicable

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

Switzerland30 participantsStarted 2007-11

Plain-language summary

The purpose of this study is to determine whether the investigators' new imaging modality (111In-exendin-4) has advantages in detecting insulinomas in comparison to conventional imaging.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Biochemically proven endogenous hyperinsulinism confirmed by hypoglycaemia with neuroglycopenic symptoms, inadequately high serum insulin and C-peptide concentrations and negative sulfonylurea screening as well as low serum beta-hydroxybutyrate concentrations * Able and willing to provide written informed consent Exclusion Criteria: * Renal insufficiency (creatinine \> 140 micromol/l) * Pregnancy or positive pregnancy test which will be performed in all patients without contraception and aged \< 50 years * Allergy to exendin-4 (Byetta®)

What they're measuring

Detection of insulinomas, cure rate

Timeframe: one year

Trial details

NCT IDNCT00937079

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-12

View on ClinicalTrials.gov More Hyperinsulinism trials